Publications about MGN1601

June, 01-05, 2012
American Society of Clinical Oncology, Annual Meeting
Chicago, USA
Efficacy and safety of cancer vaccine with 4-fold gene modified allogeneic tumor cells: results of the phase I/II ASET study in patients with advanced renal cell carcinoma (Poster)

May 24-25, 2012
CIMT (Association for Cancer Immunotherapy)
Mainz, Germany
Immunological results of a phase I/II therapeutic vaccination study by MGN1601 in patients with advanced renal cell carcinoma (Poster)

May 16-19, 2012
American Society of Gene & Cell Therapy, Annual Meeting
Philadelphia, USA
New safety and efficacy data of a phase I/II study in patients with advanced renal cell carcinoma, following vaccination with fourfold gene-modified, allogeneic tumor cells combined with a DNA-based immunomodulator (Talk)

March 31 -April 04, 2012
American Association for Cancer Research, Annual Meeting
Chicago, USA
Immune-related efficacy data of the phase I/II study of a fourfold gene-modified allogeneic tumor cell vaccine in patients with advanced renal cell carcinoma (Poster)

February 02-04, 2012
American Society of Clinical Oncology, Genitourinary Cancers Symposium
San Francisco, USA
New safety and efficacy data of the ongoing phase I-II study (ASET study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma (Poster)

May 25-27, 2011
CIMT (Association for Cancer Immunotherapy), Annual Meeting
Mainz, Germany
MGN1601, a tumor vaccine comprising allogeneic, transfected tumor cells and an immunomodulator - preliminary safety data on an ongoing phase I/II clinical study in patients with metastatic renal cell carcinoma (Poster)

May 18-21, 2011
American Society of Gene & Cell Therapy, Annual Meeting
Seattle, USA
A phase I/II clinical study of MGN1601, a tumor vaccine comprising allogeneic, gene-modified and irradiated tumor cells in combination with an immunomodulator, in patients with metastatic renal cell carcinoma (ASET study) - preliminary results (Talk)

February 17-18, 2011
American Society of Clinical Oncology, Genitourinary Cancers Symposium Orlando, USA
Preliminary safety results of an ongoing phase I/II clinical study of MGN1601, a tumor vaccine comprising allogeneic, gene-modified and irradiated tumor cells in combination with an immunomodulator in patients with metastatic renal cell carcinoma (Poster)